Allogene Therapeutics Inc (NASDAQ: ALLO) on Monday, soared 0.86% from the previous trading day, before settling in for the closing price of $1.16. Within the past 52 weeks, ALLO’s price has moved between $1.09 and $3.78.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -43.16% over the last five years. The company achieved an average annual earnings per share of 8.10%. With a float of $143.20 million, this company’s outstanding shares have now reached $212.21 million.
The firm has a total of 229 workers. Let’s measure their productivity. In terms of profitability, gross margin is -32622.73%, operating margin of -1219136.36%, and the pretax margin is -1168850.0%.
Allogene Therapeutics Inc (ALLO) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Allogene Therapeutics Inc is 34.52%, while institutional ownership is 64.70%. The most recent insider transaction that took place on Apr 21 ’25, was worth 13,537. In this transaction SVP, Finance of this company sold 9,601 shares at a rate of $1.41, taking the stock ownership to the 130,663 shares. Before that another transaction happened on Apr 21 ’25, when Company’s Officer proposed sale 9,601 for $1.41, making the entire transaction worth $13,537.
Allogene Therapeutics Inc (ALLO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 8.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.55% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Allogene Therapeutics Inc (ALLO) is currently performing well based on its current performance indicators. A quick ratio of 8.54 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12794.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.29 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Analysing the last 5-days average volume posted by the [Allogene Therapeutics Inc, ALLO], we can find that recorded value of 5.54 million was better than the volume posted last year of 4.74 million. As of the previous 9 days, the stock’s Stochastic %D was 11.59%. Additionally, its Average True Range was 0.15.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 2.97%, which indicates a significant decrease from 11.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.30% in the past 14 days, which was lower than the 114.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5926, while its 200-day Moving Average is $2.1887. Now, the first resistance to watch is $1.2400. This is followed by the second major resistance level at $1.3100. The third major resistance level sits at $1.3500. If the price goes on to break the first support level at $1.1300, it is likely to go to the next support level at $1.0900. Now, if the price goes above the second support level, the third support stands at $1.0200.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
Market capitalization of the company is 255.89 million based on 218,705K outstanding shares. Right now, sales total 20 K and income totals -257,590 K. The company made 0 K in profit during its latest quarter, and -59,940 K in sales during its previous quarter.
